NCT06336629已完成4 期
Combination Treatment of Winlevi With Duac Gel in Patients With Acne Vulgaris
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.
研究概览
简要总结
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Duac gel in combination to emulate real life practice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •i. Outpatient, male or female subjects of any race, and at least 12 years of age or older.
- •Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study:
- •A female is considered of childbearing potential unless she is:
- •postmenopausal for at least 12 months prior to study drug administration;
- •without a uterus and/or both ovaries; or
- •Has been surgically sterile for at least 6 months prior to study drug administration.
- •Reliable methods of contraception are:
- •Hormonal methods or intrauterine device in use > 90 days prior to study drug administration;
- •Barrier methods plus spermicide in use at least 14 days prior to study drug administration; or
- •Vasectomized partner (vasectomy must be performed 3 months prior to first study drug administration or in the alternative a zero sperm count will suffice).
- •Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.
- •ii. Facial acne IGA score of 3 or
- •iii. Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.
排除标准
- •i. Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
- •ii. Allergy or sensitivity to any component of the test medications. iii. Subjects who have not complied with the proper wash-out periods for prohibited medications .
- •iv. Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study.
- •v. Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris vi. Evidence of recent alcohol or drug abuse. vii. History of poor cooperation, non-compliance with medical treatment, or unreliability.
- •viii. Exposure to an investigational drug study within 30 days of the Baseline Visit.
- •ix. Patients who have demonstrated hypersensitivity (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. (4) • Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (including pseudomembranous colitis)
研究组 & 干预措施
Winlevi (clascoterone) 1% & Duac gel
Experimental
干预措施: Winlevi (clascoterone) 1% & Duac gel (Drug)
结局指标
主要结局
The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.
时间窗: Week 16
The investigator will evaluate global acne severity using the Investigator Global Assessment scale, which ranges from 0 to 5, where 0 represents clear skin and 5 represents very severe acne
次要结局
- Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline(Week 16)
- Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline.(Week 16)
- Tolerability Measures of Peeling Based on 5-point Severity Scale(Week 4,8,12,16)
- Assessment of Skin Oiliness Based on 5-point Severity Scale(Week 4,8,12,16)
- Percent of Total Lesion Reduction at Week 16 Compared to Baseline(Week 16)
- Tolerability Measures of Erythema Based on 5-point Severity Scale(Week 4,8,12,16)
- Tolerability Measures of Dryness Based on 5-point Severity Scale(Week 4,8,12,16)
- Tolerability Measures of Burning/Stinging Based on 6-point Severity Scale(Week 4,8,12,16)
- Tolerability Measures of Pruritus Based on 6-point Severity Scale(Week 4,8,12,16)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of AcneAcne VulgarisNCT06336603Sun Pharmaceutical Industries Limited20
已完成
2 期
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne VulgarisAcne VulgarisNCT01631474Intrepid Therapeutics, Inc.363
已完成
2 期
A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne VulgarisAcne VulgarisNCT03307577Therapeutics, Inc.52
Unknown
1 期
A Novel Combination Oral Agent to Treat Acne VulgarisACNE VULGARISNCT01301586Nexgen Dermatologics, Inc.60
已完成
4 期
A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With AcneAcne VulgarisNCT06415305Sun Pharmaceutical Industries Limited10